Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose, dose-ascending crossover study of inhaled GW642444M with magnesium stearate in moderate COPD
2007-001391-37Phase 2Completed
- Sponsor
- GSK
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vilanterol in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by GSK. Primary endpoint: General safety and tolerability. Started May 2007; status: completed.
02
Drugs
vilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2007-001391-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001391-37.